Kazia Therapeutics Deal History & Licensing Activity
Kazia Therapeutics is a life sciences. Over the past three years, Kazia Therapeutics has been involved in 1 licensing and acquisition transaction, with a primary focus on Peptides (2 deals). The company currently has 6 active clinical trials, primarily in Oncology.
Deals (12mo)
1
Active Trials
6
Top Modality
Peptides
Focus Area
Oncology
Kazia Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Kazia Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| MSETC | QIMR Berghofer | Peptides | Preclinical | license | Apr 2026 |
Kazia Therapeutics Pipeline Focus
Therapeutic areas and modalities where Kazia Therapeutics is most active based on deal history and clinical trial data.
Kazia Therapeutics Clinical Pipeline
Kazia Therapeutics has 6 active clinical trials across 2 development phases.
3
Phase 1
3
Phase 2
See How Your Asset Matches Kazia Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Kazia Therapeutics Licensing & Deal Activity
Kazia Therapeutics is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Kazia Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Kazia Therapeutics include Oncology (2 deals and trials), Solid Tumors (2 deals and trials), CNS Disorders (1 deal and trial), and Hematological Malignancies (1 deal and trial). In terms of modality, Kazia Therapeutics has shown particular interest in peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Kazia Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Kazia Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.